NKG2A/CD159a/KLRC1 Antibody (DMC298) - Chimeric

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-48312

Recombinant Monoclonal Antibody
Catalog #
Availability
Size / Price
Qty
NBP3-48312-100ug
NBP3-48312-10ug
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Species Reactivity

Human

Applications

Flow Cytometry

Label

Unconjugated

Antibody Source

Recombinant Monoclonal Human IgG1 Clone # DMC298

Concentration

LYOPH mg/ml

View all NKG2A/CD159a Antibodies »

Product Specifications

Immunogen

NKG2A/CD159a/KLRC1 recombinant protein expressed in mammalian cells (Accession# P26715). The exact amino acid sequence is proprietary.

Clonality

Monoclonal

Host

Human

Isotype

IgG1

Description

This product is shipped at ambient temperature. Store at -20C to -80C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80C (Avoid repeated freezing and thawing).

Scientific Data Images for NKG2A/CD159a/KLRC1 Antibody (DMC298) - Chimeric

NKG2A/CD159a/KLRC1 Antibody (DMC298) - Chimeric

Flow Cytometry: NKG2A/CD159a/KLRC1 Antibody (DMC298) - Chimeric [NBP3-48312]

Flow cytometry analysis with Anti-NKG2A/CD159a/KLRC1/CD159a/KLRC1 (DMC298) on HEK293 cells transfected with human NKG2A/CD159a/KLRC1/CD159a/KLRC1 (Blue histogram) or HEK293 transfected with irrelevant protein (Red histogram).

Applications for NKG2A/CD159a/KLRC1 Antibody (DMC298) - Chimeric

Application
Recommended Usage

Flow Cytometry

1:100

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified from cell culture supernatant

Reconstitution

Dissolve the lyophilized antibody in sterile and low endotoxin water. The recommend volume of water is lot specific. Please refer to the instructions printed on the product vial or contact technical support.

Formulation

PBS, pH 7.4, 5-8% Trehalose

Preservative

Trehalose

Concentration

LYOPH mg/ml

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at -20C in powder form. Store at -80C once reconstituted.

Background: NKG2A/CD159a

NK group 2 member A (NKG2A), also known as killer lectin like receptor c1 (KLRC1) and CD159a, is a ~38 kDa type II transmembrane protein belonging to the C-type lectin superfamily and plays a role in suppression of cytotoxic CD8+ T cell activity and functions as an immune checkpoint (1,2). NKG2A belongs to a group of natural killer (NK) cell inhibitor receptors (IRs) which includes killer immunoglobulin receptors (KIRs), lymphocyte activation gene-3 (LAG-3), T cell immunoreceptor with Ig and ITIM domains (TIGIT), programmed death ligand-1 (PD-1), and T cell immunoglobulin mucin-3 (TIM-3) (1,3). NKG2A is synthesized as a protein of 233 amino acids (aa) with a theoretical molecular weight of 26.3 kDa and is expressed on CD56hi NK cells, NKT cells, and some CD8+ alphabeta T cells (2,4). Together with CD94, NKG2A forms a heterodimer and acts as a receptor for the MHC Class I molecular human leukocyte antigen (HLA)-E (1-3). The NKG2A/CD94 receptor interaction with the HLA-E ligand results in phosphorylation of NKG2A's immunoreceptor tyrosine-based inhibition motifs (ITIMs), causing suppression of activating signals from immunoreceptor tyrosine-based activation motif (ITAM)- containing T cell receptors (TCR) or other activating receptors like NKG2D, via the intracellular phosphatase SHP1 (2,3,5). Overall, cancer cells utilize the NKG2A-HLA-E interaction and signaling to evade immune surveillance by NK cells and T cells (1-3,5-6).

Similar to cytotoxic T lymphocyte associated protein 4 (CTLA-4) and PD-1, NKG2A has become a prominent target for immune checkpoint blockade and cancer immunotherapy (1-3,5-6). Monalizumab is a novel IgG4 monoclonal antibody developed for blocking NKG2A's interaction with HLA-E and has shown promising results in clinical trials (1-3,5-6). In addition to being used as a single agent, it is being studied as a possible combination therapy with other blocking antibodies such as anti-PD-L1 and anti-epidermal growth factor receptor (EGFR) (2,5,6).

References

1. Alfarra, H., Weir, J., Grieve, S., & Reiman, T. (2020). Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy. Frontiers in immunology, 11, 575609. https://doi.org/10.3389/fimmu.2020.575609

2. Creelan, B. C., & Antonia, S. J. (2019). The NKG2A immune checkpoint - a new direction in cancer immunotherapy. Nature reviews. Clinical oncology, 16(5), 277-278. https://doi.org/10.1038/s41571-019-0182-8

3. Zaghi, E., Calvi, M., Marcenaro, E., Mavilio, D., & Di Vito, C. (2019). Targeting NKG2A to elucidate natural killer cell ontogenesis and to develop novel immune-therapeutic strategies in cancer therapy. Journal of leukocyte biology, 105(6), 1243-1251. https://doi.org/10.1002/JLB.MR0718-300R

4. Uniprot (P26715)

5. Borst, L., van der Burg, S. H., & van Hall, T. (2020). The NKG2A-HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(21), 5549-5556. https://doi.org/10.1158/1078-0432.CCR-19-2095

6. Andre, P., Denis, C., Soulas, C., Bourbon-Caillet, C., Lopez, J., Arnoux, T., Blery, M., Bonnafous, C., Gauthier, L., Morel, A., Rossi, B., Remark, R., Breso, V., Bonnet, E., Habif, G., Guia, S., Lalanne, A. I., Hoffmann, C., Lantz, O., Fayette, J., ... Vivier, E. (2018). Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells. Cell, 175(7), 1731-1743.e13. https://doi.org/10.1016/j.cell.2018.10.014

Long Name

Natural Killer G2A

Alternate Names

CD159a, Klrc1, NKG2

Gene Symbol

KLRC1

Additional NKG2A/CD159a Products

Product Documents for NKG2A/CD159a/KLRC1 Antibody (DMC298) - Chimeric

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Product Specific Notices for NKG2A/CD159a/KLRC1 Antibody (DMC298) - Chimeric

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy Policy
Cookie Policy
Site Map
© Copyright 2026 Bio-Techne. All Rights Reserved. All trademarks and registered trademarks are the property of Bio-Techne and its brands unless otherwise specified.